Professor at Shenzhen Polytechnic University, China
Professor Naihan Xu is a leading researcher and educator in the field of tumor biology and molecular medicine, currently serving as a Professor and Doctoral Supervisor at the School of Food and Drug, Shenzhen Polytechnic University. With over two decades of academic and research experience, Dr. Xu has made substantial contributions to understanding cancer pathogenesis and developing targeted therapeutic strategies. Previously, she held a long-term appointment at the Tsinghua Shenzhen International Graduate School of Tsinghua University, where she played a critical role in biopharmaceutical education and translational research. Her academic journey has been marked by dedication to cellular signaling mechanisms, tumor microenvironment regulation, and the development of molecular tools for cancer diagnostics and treatment.
Profile
Scopus
Education
Dr. Xu received her doctoral training in molecular biology and tumor research, supported by an international research fellowship at the prestigious Cancer Research UK Beatson Institute in Glasgow, where she focused on signal transduction in malignancy. Her foundational education laid the groundwork for a robust career in both teaching and research, emphasizing cross-disciplinary approaches that integrate biochemistry, bioinformatics, and molecular diagnostics. This academic background has been pivotal in shaping her research into complex biological systems governing tumor progression and therapy resistance.
Experience
Dr. Xu began her academic career as a lecturer at the Tsinghua Graduate School in Shenzhen in 2010, swiftly rising to Associate Professor and Doctoral Supervisor due to her research productivity and mentoring capacity. From 2011 to 2023, she played a central role at Tsinghua University’s Institute of Biopharmaceutical and Health Engineering, where she supervised numerous doctoral theses and coordinated major grant-funded projects. In 2023, she joined Shenzhen Polytechnic University, where she now leads advanced research on drug discovery and functional diagnostics. Throughout her career, Dr. Xu has fostered interdisciplinary collaborations and contributed to national and international scientific communities.
Research Interest
Her research interests lie at the intersection of tumor biology, signal transduction, and therapeutic innovation. Dr. Xu’s work explores autophagy, tumor metabolism, ubiquitin-proteasome pathways, and cell cycle checkpoints to uncover novel regulatory mechanisms in cancer cells. She is particularly recognized for her focus on non-coding RNAs, peptide-based therapies, and fluorescence-based detection systems. Her studies leverage multi-omics approaches and bioinformatics tools to identify novel molecular targets and understand drug resistance, emphasizing translational impact. Notably, her research extends into precision medicine, using molecular probes and natural small molecules to develop personalized cancer treatments and diagnostic platforms.
Award
Dr. Xu has been the recipient of several prestigious research grants and honors. She has led major projects funded by the National Natural Science Foundation of China (NSFC), including studies on microRNA-regulated autophagy in breast cancer and natural compound inhibitors of DNA damage repair. Additionally, she was recognized by the Shenzhen Science and Technology Innovation Commission through multiple discipline layout and international collaboration projects. Her contributions have positioned her as a prominent figure in the field of cancer signaling research, and she has been nominated for national-level awards for excellence in biopharmaceutical innovation and mentorship.
Publications
Among her extensive body of work, Dr. Xu’s notable publications include:
- Genes & Diseases (2025): “Nuclear and cytoplasmic USP30-AS1 coordinately regulates breast cancer progression” – cited by 21 articles.
- Inflammation (2024): “USP30-AS1 suppresses colon cancer cell inflammation response through NF-κB/MYBBP1A signaling” – cited by 13 articles.
- Biosensors (2024): “Point-of-Care SARS-CoV-2 Detection with Chemiluminescence” – cited by 17 articles.
- ACS Applied Materials & Interfaces (2023): “Hybrid Polyplexes for Nucleic Acid Delivery” – cited by 11 articles.
- International Journal of Molecular Sciences (2023): “Autophagy-Associated lncRNAs in Neurodegeneration” – cited by 19 articles.
- Antioxidants (2023): “Canagliflozin Delays Endothelial Aging via ROS/p38/JNK” – cited by 16 articles.
- Frontiers in Immunology (2022): “Exon Screening-Based Prognosis Model in Glioma” – cited by 25 articles.
Each of these contributions reflects Dr. Xu’s sustained focus on mechanistic insights into disease and translational potential in diagnostics or therapeutics.
Conclusion
Dr. Naihan Xu’s scientific trajectory is characterized by a deep commitment to advancing cancer biology through integrative and translational research. Her prolific publication record, successful mentoring of doctoral candidates, and leadership in multi-institutional research initiatives underscore her role as a pivotal figure in China’s biopharmaceutical research landscape. With a forward-looking approach to molecular diagnostics, RNA biology, and therapeutic peptide development, Dr. Xu continues to shape the next generation of oncological research and clinical application. Her nomination for academic and research awards is a recognition of not only her individual excellence but also her enduring impact on scientific innovation and higher education.